ストックスクリーナーアプリを入手
8.33
13.95%
1.02
前日終値:
$7.31
開ける：
$7.58
24時間の取引高:
14.27M
Relative Volume:
10.52
時価総額：
$820.09M
収益：
$14.79M
当期純損益:
$-191.78M
株価収益率:
-4.2795
EPS:
-1.9465
ネットキャッシュフロー:
$-172.86M
1週間 パフォーマンス:
+15.37%
1か月 パフォーマンス:
+27.96%
6か月 パフォーマンス:
+57.77%
1年 パフォーマンス:
+79.14%
1日の値動き範囲:
$7.49
$8.42
1週間の範囲:
$6.95
$8.42
52週間の値動き範囲:
$3.79
$8.8661
Solid Biosciences Inc Stock (SLDB) Company Profile
名前
Solid Biosciences Inc
セクター
電話
617-337-4680
住所
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
8.33 | 820.09M | 14.79M | -191.78M | -172.86M | -1.9465 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-20 | 開始されました | Guggenheim | Buy |
| 2025-12-04 | 開始されました | Needham | Buy |
| 2025-06-26 | 開始されました | Citigroup | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-13 | 開始されました | Wedbush | Outperform |
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-15 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-06-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 再開されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | William Blair | Outperform |
| 2024-03-15 | 開始されました | Citigroup | Buy |
| 2024-03-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-07-12 | 開始されました | Piper Sandler | Neutral |
| 2021-05-27 | 開始されました | Jefferies | Buy |
| 2021-03-16 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2021-01-08 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 開始されました | Evercore ISI | Outperform |
| 2019-08-29 | ダウングレード | Citigroup | Neutral → Sell |
| 2019-08-19 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | ダウングレード | Goldman | Neutral → Sell |
| 2019-02-08 | アップグレード | Citigroup | Sell → Neutral |
| 2019-02-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 開始されました | Citigroup | Sell |
| 2018-09-06 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Solid Biosciences Inc (SLDB) 最新ニュース
Selling US$823k Of Solid Biosciences Stock Rewarded Insiders - Moomoo
Solid Biosciences Inc (SLDB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Solid Biosciences Inc (SLDB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Solid Biosciences Inc (SLDB) Institutional Confidence - TradingKey
Solid Biosciences Inc (SLDB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Solid Biosciences Inc (SLDB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Solid Biosciences Inc. targets platform partnerships at BIO2026 in San Diego - Traders Union
Solid Biosciences Inc (SLDB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Solid Biosciences Inc (SLDB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Solid Biosciences Inc (SLDB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Solid Biosciences grants 77,500 options to director | SLDB Insider Trading - Stock Titan
Director at Solid Biosciences (NASDAQ: SLDB) granted 77,500 options - Stock Titan
Solid Biosciences (SLDB) director awarded 77,500 stock options at $6.61 strike - Stock Titan
Solid Biosciences (SLDB) director awarded 77,500 options via Perceptive Advisors - Stock Titan
Director at Solid Biosciences (SLDB) granted 77,500 stock options at $6.61 - Stock Titan
Solid Biosciences (SLDB) director receives 77,500 stock options at $6.61 exercise price - Stock Titan
Director at Solid Biosciences (NASDAQ: SLDB) receives 77,500 stock options grant - Stock Titan
Solid Biosciences (SLDB) grants director 77,500 stock options at $6.61 - Stock Titan
Solid Biosciences director granted 77,500 options | SLDB Insider Trading - Stock Titan
Solid Biosciences Shareholders Approve Directors and Share Increase - TipRanks
Solid Biosciences (NASDAQ: SLDB) shareholders approve doubling authorized stock - Stock Titan
Solid Biosciences Inc. targets industry collaboration ahead of BIO2026 to accelerate genetic medicine - Traders Union
Should I Buy SLDB (Solid Biosciences Inc.) | AI Analysis, Technical & News Insights - Kavout
SLDB: Gene therapy programs show robust efficacy, safety, and regulatory momentum for key indications - TradingView
Solid Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB) - The Globe and Mail
SLDB (NASDAQ: SLDB) supplement lists updated selling stockholders and holdings - Stock Titan
Solid Biosciences Rises as Investors Focus on Rare-Disease Pipeline - Bez Kabli
H.C. Wainwright raises Solid Biosciences price target on FA trial progress - Investing.com UK
SLDB Maintained by HC Wainwright & Co. -- Price Target Raised to $25 - GuruFocus
SLDB: Duchenne and FA gene therapy programs show strong progress, with pivotal FDA meetings ahead - TradingView
H.C. Wainwright raises Solid Biosciences price target on FA trial progress By Investing.com - Investing.com South Africa
Solid Biosciences And Nanomosaic Announce Co-Marketing Agreement To Advance Gene Therapy Delivery And Analytics - TradingView
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics - PR Newswire
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences joins Jefferies Global Healthcare Conference with CEO Bo Cumbo fireside chat - Traders Union
Watch Solid Biosciences CEO at two June healthcare investor events - Stock Titan
Solid Biosciences to Participate at Upcoming Investor Conferences - The Manila Times
Solid Biosciences Inc. (SLDB) Gains 3.82% as Shares Approach Key Resistance at $7.71Momentum Stock Picks - The Legal Advocate
Solid Biosciences (SLDB) Edges Higher, Testing Key Resistance After Recent GainsIchimoku Cloud - The Legal Advocate
Solid Biosciences Inc. spotlights Patrick González SGT-003 insights at major DMD conference - Traders Union
Solid Biosciences begins phase 3 trial for Duchenne therapy By Investing.com - Investing.com Nigeria
Solid Biosciences (SLDB) Surges 3.93% as Bullish Momentum BuildsCall Resistance - The Legal Advocate
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
Solid Biosciences Inc. (SLDB) Q1 2026 Earnings: Wider Loss Reported as Pipeline Investment ContinuesUpward Estimate Revision - thelegaladvocate.com
J.P. Morgan Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
SLDB Q1 2026 Earnings: Wider-than-Expected Loss as Solid Biosciences Advances Gene Therapy PipelineEstimate Revision Count - newsline.com
SLDB Stock Price, Quote & Chart | SOLID BIOSCIENCES INC (NASDAQ:SLDB) - ChartMill
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months? - Insider Monkey
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Solid Biosciences Inc (SLDB) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):